Cerebrotendinous Xanthomatosis (CTX) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025
Cerebrotendinous Xanthomatosis (CTX) Emerging Therapy and TPP Insights Thelansis’s “Cerebrotendinous Xanthomatosis (CTX) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Cerebrotendinous Xanthomatosis (CTX) Overview Cerebrotendinous xanthomatosis (CTX) is a lipid storage disorder characterized by a spectrum of clinical manifestations starting from early infancy to adulthood. Initial symptoms often include chronic diarrhea or neonatal cholestasis. Childhood-onset cataracts are common, typically appearing within the first decade of life in about 75% of affected individuals. Tendon xanthomas, predominantly in the second or third decade, manifest as deposits on various tendons such as the Achilles, extensor tendons of the elbo...